Genetics and genomics of pulmonary arterial hypertension

Soubrier, Florent and Chung, Wendy K. and Machado, Rajiv and Grunig, Ekkehard and Aldred, Michaela and Geraci, Mark and Loyd, James E. and Elliott, C. Gregory and Trembath, Richard C. and Newman, John H. and Humbert, Marc (2013) Genetics and genomics of pulmonary arterial hypertension. Journal of the American College of Cardiology, 62 (25 SUP). D13-D21. ISSN 0735-1097

Full content URL: http://dx.doi.org/10.1016/j.jacc.2013.10.035

Documents
Soubrier et al_JACC2013.pdf

Request a copy
12842 Genetics and Genomics of Pulmonary Arterial Hypertension.pdf
[img]
[Download]
[img] PDF
Soubrier et al_JACC2013.pdf - Whole Document
Restricted to Repository staff only

274kB
[img]
Preview
PDF
12842 Genetics and Genomics of Pulmonary Arterial Hypertension.pdf - Whole Document

207kB
Item Type:Review
Item Status:Live Archive

Abstract

Major discoveries have been obtained within the last decade in the field of hereditary predisposition to pulmonary arterial hypertension (PAH). Among them, the identification of bone morphogenetic protein receptor type 2 (BMPR2) as the major predisposing gene and activin A receptor type II-like kinase-1 (ACVRL1, also known as ALK1) as the major gene when PAH is associated with hereditary hemorrhagic telangiectasia. The mutation detection rate for the known genes is approximately 75 in familial PAH, but the mutation shortfall remains unexplained even after careful molecular investigation of these genes. To identify additional genetic variants predisposing to PAH, investigators harnessed the power of next-generation sequencing to successfully identify additional genes that will be described in this report. Furthermore, common genetic predisposing factors for PAH can be identified by genome-wide association studies and are detailed in this paper. The careful study of families and routine genetic diagnosis facilitated natural history studies based on large registries of PAH patients to be set up in different countries. These longitudinal or cross-sectional studies permitted the clinical characterization of PAH in mutation carriers to be accurately described. The availability of molecular genetic diagnosis has opened up a new field for patient care, including genetic counseling for a severe disease, taking into account that the major predisposing gene has a highly variable penetrance between families. Molecular information can be drawn from the genomic study of affected tissues in PAH, in particular, pulmonary vascular tissues and cells, to gain insight into the mechanisms leading to the development of the disease. High-throughput genomic techniques, on the basis of next-generation sequencing, now allow the accurate quantification and analysis of ribonucleic acid, species, including micro-ribonucleic acids, and allow for a genome-wide investigation of epigenetic or regulatory mechanisms, which include deoxyribonucleic acid methylation, histone methylation, and acetylation, or transcription factor binding. © 2013 by the American College of Cardiology Foundation. Published by Elsevier Inc.

Additional Information:Supplement, Updates in Pulmonary Hypertension
Keywords:BMPR2, Genetics, Genomic, Pulmonary hypertension
Subjects:C Biological Sciences > C431 Medical Genetics
Divisions:College of Science > School of Life Sciences
Related URLs:
ID Code:12842
Deposited On:06 Jan 2014 10:06

Repository Staff Only: item control page